ePrints

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B

Lookup NU author(s): Dr Steven Hardy, Professor Tim Goodship

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background Atypical haemolytic uraemic syndrome (aHUS) is caused by dysregulated complement activation. A humanised anti-C5 monoclonal antibody has recently become available for treatment of this condition Case-Diagnosis/Treatment We present the first description of an infant with an activating mutation of complement factor B successfully treated with eculizumab. On standard doses she had evidence of ongoing C5 cleavage despite a good clinical response. Conclusions Eculizumab is effective therapy for aHUS associated with factor B mutations, but recommended doses may not be adequate for all patients.

Publication metadata

Author(s): Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH

Publication type: Article

Publication status: Published

Journal: Pediatric Nephrology

Year: 2013

Volume: 28

Issue: 8

Pages: 1315-1318

Print publication date: 28/04/2013

ISSN (print): 0931-041X

ISSN (electronic): 1432-198X

Publisher: Springer

URL: http://dx.doi.org/10.1007/s00467-013-2492-x

DOI: 10.1007/s00467-013-2492-x

Altmetrics

Share